RT Journal Article
SR Electronic
T1 Gene expression levels of the glycolytic enzymes lactate dehydrogenase A (LDHA) and phosphofructokinase platelet (PFKP) are good predictors of survival time, recurrence and risk of death in cervical cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.02.22277946
DO 10.1101/2022.08.02.22277946
A1 Bolaños-Suárez, Verónica
A1 Alfaro, Ana
A1 Espinosa, Ana María
A1 Medina-Martínez, Ingrid
A1 Juárez, Eligia
A1 Villegas-Sepúlveda, Nicolás
A1 Gudiño-Zayas, Marco
A1 Gutiérrez-Castro, América
A1 Román-Bassaure, Edgar
A1 Salinas-Nieves, María Eugenia
A1 Bruno-Muñoz, Sergio
A1 Flores-Herrera, Oscar
A1 Berumen, Jaime
YR 2022
UL http://medrxiv.org/content/early/2022/08/03/2022.08.02.22277946.abstract
AB Background Up to 74% of patients with cervical cancer (CC) may experience recurrence after their treatment, and most of them are identified late when only the clinical parameters are used, which decreases their chances of recovery. Molecular markers can improve the prediction of clinical outcome and identify therapeutic targets in CC. Glycolysis is altered in 70% of CCs, so it could be a metabolic pathway in which molecular markers associated with the aggressiveness of CC can be identified.Methods The expression of 14 glycolytic genes was analyzed in 118 CC samples by microarrays, and only LDHA and PFKP were validated by qRT–PCR (n=58) and in second and third replicates by Western blotting (n=69) and immunohistochemistry (n=18).Results LDHA and PFKP were associated with poor overall survival [OS: LDHA HR=3.0 (95% CI= 1.1-8.2); p=2.9 × 10-2; PFKP HR=3.4 (95% CI= 1.1-10.5); p= 3.5 × 10-2] and disease-free survival [DFS: LDHA HR=2.7 (95% CI= 1.6-6.3); p=2.6 × 10-2] independent of FIGO clinical stage. The risk of death was greater when both biomarkers were overexpressed than when using only FIGO stage [HR =7 (95% CI 1.6-31.1, p=1.0 × 10-2) versus HR=8.1 (95% CI=2.6-26.1; p=4.3 × 10-4)] and increased exponentially as the expression of LDHA and PFKP increased.Conclusions LDHA and PFKP at the mRNA and protein levels were associated with poor overall survival, disease-free survival and increased risk of death of patients with CC regardless of FIGO stage. The measurement of expression of these two markers could be very useful to evaluate the clinical evolution and the risk of death from CC and to make better therapeutic decisions at the beginning of treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by National Council on Science and Technology (Conacyt) under grant numbers 8135/A1, 24341 (to JB) and Laboratory Huella GenicaAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the General Hospital of Mexico (HGM) gave ethical approval for this work (approval number DIC/03/311/04/051).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE52904; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE39001 ADPGKADP-dependent glucokinaseALDOAaldolaseAUCarea under the curveCCcervical cancerDFSdisease-free survivalEDARADDEDAR-associated death domainENO1enolase 1FIGOInternational Federation of Gynecology and ObstetricsFCfold changeGPIglucose-6-phosphate isomeraseGAPDHglyceraldehyde-3-phosphate dehydrogenaseHG-CINhigh-grade cervical intraepithelial neoplasiaHK2hexokinase 2HRhazard ratioIHimmunohistochemistryLDHAlactate dehydrogenase AOSoverall survivalPFKPphosphofructokinase plateletPGK1phosphoglycerate kinasePKMpyruvate kinase MqRT–PCRquantitative real-time-polymerase chain reactionSLC2A1solute carrier family 2 member 1SLC9A1solute carrier family 9 member A1TP1P1triosephosphate isomerase 1 pseudogene 1WBWestern blotting